AtheroNova operates through its wholly owned subsidiary, AtheroNova Operations Inc., as an early stage biotech company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. AHRO has developed intellectual property for a class of compounds designed to reduce the incidence and severity of atherosclerosis. For more information visit the company’s Web site at www.atheronova.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: